Quanterix Corporation (QTRX) Expands Alzheimer's Test Distribution in New Jersey

Quanterix (QTRX) signed an exclusive deal with Sherman Abrams Laboratory to distribute its LucentAD Complete Alzheimer's blood test in Metro New York and New Jersey. Financial details were not disclosed.

Original reporting
Published Nov 16, 2026, 6:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 6:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Quanterix Corporation (QTRX) Expands Alzheimer's Test Distribution in New Jersey — source image
Decision brief

The 30-second read

$QTRXNeutralLow
01

Why it matters

The agreement expands geographic reach but offers no immediate financial impact.

02

Market read

A modest corporate partnership with limited immediate trading relevance.

03

What to watch

Potential regulatory or reimbursement hurdles could limit test adoption.

Relevance 5/10Novelty 4/10Timing: immediate

Background

Quanterix provides ultra-sensitive protein detection platforms; its Alzheimer's test is a novel blood-based diagnostic.

Company-level read

Ticker impact

$QTRXNeutralMedium confidence
Context

Quanterix announced an exclusive distribution agreement for its Alzheimer's blood test in New Jersey and New York.

Expected impact

possible slight upside as investors price early adoption potential

Evidence & confidence

No financial terms disclosed; impact depends on future test uptake.

Market effects

May signal growing interest in Alzheimer's diagnostics within the biotech sector.

Limited to New Jersey/New York healthcare market.

Minimal; no broader macro effect.

Counterpoint

Without disclosed volumes, the deal may not translate into meaningful revenue.

Key entities

  • Quanterix Corporation

    Developer of the Alzheimer's blood test.

  • Sherman Abrams Laboratory

    Exclusive distributor for the test in the region.

Related articles

$QTRXMed

What Quanterix (QTRX) Said on Its Q3 Earnings Call

Quanterix (QTRX) reported a Q3 net loss of $21.6M, improved from last year. Adjusted EBITDA loss was $12.2M. Gross margin rose to 47.4%. LucentAD test volume doubled, but revenue from diagnostics fell to $1.2M. The company expects 2026 gross margin of 48-50% and $70M cash. Alzheimer's test discussions with FDA continue, with no clearance date given.

$QTRXMed

Quanterix Releases Financial Results for the Third Quarter of 2026

Quanterix Corp (QTRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Quanterix Releases Financial Results for the Third Quarter of 2026 Reports $35.0 million in revenue, up 6.3% sequentially, and $80.7 million of cash and marketable securities Initiatives to accelerate commercial effectiveness position the Company for growth in rest o

$QTRXHighAI 9/10

Quanterix (QTRX) Q2 2026 Earnings Call Transcript

Quanterix (QTRX) said Q2 2026 revenue was about $3 million (9%) below May guidance, citing broad-based shortfalls and commercial execution challenges. The company lowered 2026 revenue guidance to $142 million to $148 million from $169 million to $174 million and expects ~$80 million cash by year-end. Quanterix added commercial leaders (Jim Gute, Geoff Albrecht) and reorganized sales, citing Akoya integration savings of $85 million annually.

$QTRXMed

Quanterix Reshapes Sales Strategy, Targets Q4 FDA Decision for Alzheimer’s Blood Test

Quanterix (QTRX) said it completed Akoya Biosciences integration in Q2 and delivered $85M in revenue synergies. It is reshaping sales teams and expects clinical-trial bookings to rise QoQ. For its LucentAD Complete Alzheimer’s blood test, Quanterix filed a 510(k) in January and targets an FDA decision in Q4, possibly into Q1, citing a CMS price crosswalk of $897. It targets $10M diagnostics revenue in 2026.